Volume Share Of Biosimilars

Interestingly, in the case of the biosimilars, both Korean and Indian firms accounted for a third of volume with the report noting that these companies essentially manufacture these products, with marketing handled by US partner firms.

“This reflects the importance of collaborations and the complexity of marketing biosimilars in the US, which have seen varying degrees of uptake across molecules as originators use a variety of techniques to defend their market share,” the IQVIA report maintained.

The US Food and Drug Administration has greenlighted 50 biosimilars for 15 different reference biologics as of 26 April 2024. Henlius and Accord BioPharma’s partnered Hercessi (trastuzumab-strf) rival to Herceptin was the 50th biosimilar to get the agency’s go-ahead.(Also see "FDA Makes It 50 With Accord Trastuzumab Biosimilar Approval" - Generics Bulletin, 1 May, 2024.) Samsung Bioepis Co., Ltd. and Celltrion have led the Korean charge in the segment, while India’s Biocon, Ltd. has had its share of firsts in the US biosimilars market.

Celltrion has been transitioning to a direct sales model in the US, while post the integration of the acquired Viatris Inc. business Biocon Biologics has a commercial footprint across roughly 120 countries with a direct presence in the US, Canada, Europe and nine emerging markets.(Also see "Celltrion CCO On The Big US Build-Up, Direct Sales Model" - Scrip, 26 April, 2023.)

Hypertension To Mental Health Drugs: Indian Firms Supplied Bulk Of Rx Volume In US

More from Business

More from Scrip